SAN FRANCISCO (GenomeWeb News) - Several molecular diagnostic firms are looking to unveil new assays and instrument systems that could greatly expand their market presence, company executives told investors at the JP Morgan Healthcare Conference held here this week.

Qiagen, which currently has a molecular diagnostic assay portfolio of around 120 tests, is planning to launch new instruments over the next couple of years targeting the entire molecular diagnostics market, from point of care to high-throughput labs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.